Related Experiment Video

Updated: Aug 18, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics

Reneé C Ireton1, Jin Chen

  • 1Department of Medicine, Division of Rheumatology and Immunology, Vanderbilt Univesrity School of Medicine, Nashville, TN 37232, USA.

Current Cancer Drug Targets
|May 17, 2005
PubMed

Insights

EphA2 receptor tyrosine kinases are overexpressed in many cancers, mediating interactions in tumor cells and the microenvironment. Inhibiting EphA2 offers a promising strategy to simultaneously target multiple aspects of cancer progression.

Area of Science:

  • Molecular biology
  • Oncology
  • Developmental biology

Background:

  • Eph receptors (a family of receptor tyrosine kinases) and their ephrin ligands are crucial for embryonic development.
  • Eph receptor tyrosine kinases (RTKs) and ephrins are frequently overexpressed in various cancers.
  • EphA2 is notably overexpressed in breast, prostate, lung, and colon cancers.

Purpose of the Study:

  • To review the multifaceted roles of EphA2 in cancer progression.
  • To explore the mechanisms through which EphA2 inhibition can impede cancer advancement.
  • To summarize pre-clinical findings on EphA2 inhibition in diverse cancer models.

Main Methods:

  • Literature review of EphA2 function in cancer.
  • Analysis of EphA2 signaling pathways in tumor cells and the tumor microenvironment.
  • Compilation of pre-clinical data from various cancer model systems.

Main Results:

  • EphA2 plays a role in cell-cell interactions within tumor cells and the tumor microenvironment (stroma and vasculature).
  • Unlike traditional oncogenes, EphA2's influence extends beyond tumor cells.
  • Targeting EphA2 presents a potential strategy to inhibit multiple facets of tumor progression simultaneously.

Conclusions:

  • EphA2 is a significant contributor to cancer progression through its interactions in tumor cells and the surrounding microenvironment.
  • Inhibition of EphA2 is a promising therapeutic avenue for cancer treatment.
  • Pre-clinical studies support the potential of targeting EphA2 to halt cancer progression.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.